TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdel Khalek, S. A1 - Abdelalim, A. A. T1 - Search for the Standard Model Higgs boson in the H→WW(⋆)→ℓνℓνH→WW(⋆)→ℓνℓν decay mode with 4.7 fb\(^{−1}\) of ATLAS data at \(\sqrt{s}\)=7 TeV JF - Physics Letters B N2 - A search for the Standard Model Higgs boson in the H→WW(⋆)→ℓνℓνH→WW(⋆)→ℓνℓν (ℓ=e,μℓ=e,μ) decay mode is presented. The search is performed using proton–proton collision data corresponding to an integrated luminosity of 4.7 fb\(^{−1}\) at a centre-of-mass energy of 7 TeV collected during 2011 with the ATLAS detector at the Large Hadron Collider. No significant excess of events over the expected background is observed. An upper bound is placed on the Higgs boson production cross section as a function of its mass. A Standard Model Higgs boson with mass in the range between 133 GeV and 261 GeV is excluded at 95% confidence level, while the expected exclusion range is from 127 GeV to 233 GeV. KW - ATLAS KW - LHC KW - Higgs KW - WW Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127307 VL - 761 IS - 1 ER - TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdelalim, A. A. A1 - Abdesselam, A. T1 - Electron performance measurements with the ATLAS detector using the 2010 LHC proton-proton collision data JF - The European Physical Journal C N2 - Detailed measurements of the electron performance of the ATLAS detector at the LHC are reported, using decays of the Z, W and J/ψ particles. Data collected in 2010 at s√=7 TeV are used, corresponding to an integrated luminosity of almost 40 pb\(^{−1}\). The inter-alignment of the inner detector and the electromagnetic calorimeter, the determination of the electron energy scale and resolution, and the performance in terms of response uniformity and linearity are discussed. The electron identification, reconstruction and trigger efficiencies, as well as the charge misidentification probability, are also presented. KW - electromagnetic calorimeter KW - Atlas detector KW - calorimeter Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127313 VL - 72 IS - 1909 ER - TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdelalim, A. A. A1 - Abdesselam, A. T1 - Performance of the ATLAS Trigger System in 2010 JF - The European Physical Journal C N2 - Proton–proton collisions at √s=7 TeV and heavy ion collisions at \(\sqrt{sNN}\)=2.76 TeV were produced by the LHC and recorded using the ATLAS experiment’s trigger system in 2010. The LHC is designed with a maximum bunch crossing rate of 40 MHz and the ATLAS trigger system is designed to record approximately 200 of these per second. The trigger system selects events by rapidly identifying signatures of muon, electron, photon, tau lepton, jet, and B meson candidates, as well as using global event signatures, such as missing transverse energy. An overview of the ATLAS trigger system, the evolution of the system during 2010 and the performance of the trigger system components and selections based on the 2010 collision data are shown. A brief outline of plans for the trigger system in 2011 is presented. KW - ATLAS KW - Trigger System Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127321 VL - 72 IS - 1849 ER - TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdelalim, A. A. A1 - Abdesselam, A. T1 - Forward-backward correlations and charged-particle azimuthal distributions in pp interactions using the ATLAS detector JF - Journal of High Energy Physics N2 - Using inelastic proton-proton interactions at s√=900 GeV and 7 TeV, recorded by the ATLAS detector at the LHC, measurements have been made of the correlations between forward and backward charged-particle multiplicities and, for the first time, between forward and backward charged-particle summed transverse momentum. In addition, jet-like structure in the events is studied by means of azimuthal distributions of charged particles relative to the charged particle with highest transverse momentum in a selected kinematic region of the event. The results are compared with predictions from tunes of the pythia and herwig++ Monte Carlo generators, which in most cases are found to provide a reasonable description of the data. KW - Hadron-Hadron Scattering Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127336 VL - 7 IS - 19 ER - TY - JOUR A1 - Abdelmohsen, Usama Ramadan A1 - Szesny, Matthias A1 - Othman, Eman Maher A1 - Schirmeister, Tanja A1 - Grond, Stepanie A1 - Stopper, Helga A1 - Hentschel, Ute T1 - Antioxidant and Anti-Protease Activities of Diazepinomicin from the Sponge-Associated Micromonospora Strain RV115 N2 - Diazepinomicin is a dibenzodiazepine alkaloid with an unusual structure among the known microbial metabolites discovered so far. Diazepinomicin was isolated from the marine sponge-associated strain Micromonospora sp. RV115 and was identified by spectroscopic analysis and by comparison to literature data. In addition to its interesting preclinical broad-spectrum antitumor potential, we report here new antioxidant and anti-protease activities for this compound. Using the ferric reducing antioxidant power (FRAP) assay, a strong antioxidant potential of diazepinomicin was demonstrated. Moreover, diazepinomicin showed a significant antioxidant and protective capacity from genomic damage induced by the reactive oxygen species hydrogen peroxide in human kidney (HK-2) and human promyelocytic (HL-60) cell lines. Additionally, diazepinomicin inhibited the proteases rhodesain and cathepsin L at an IC50 of 70–90 μM. It also showed antiparasitic activity against trypomastigote forms of Trypanosoma brucei with an IC50 of 13.5 μM. These results showed unprecedented antioxidant and anti-protease activities of diazepinomicin, thus further highlighting its potential as a future drug candidate. KW - Biologie KW - diazepinomicin KW - anti-protease KW - antioxidant KW - actinomycetes KW - Micromonospora Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-76279 ER - TY - THES A1 - Adler, Melanie T1 - New approaches to improve prediction of drug-induced liver injury T1 - Neue Ansätze zur verbesserten Vorhersage arzneimittelinduzierter Leberschäden N2 - Das häufige Scheitern neuer Arzneistoffkandidaten aufgrund von Lebertoxizität in präklinischen und klinischen Studien stellt ein erhebliches Problem in der Entwicklung von neuen Arzneimitteln dar. Deshalb ist es wichtig, neue Ansätze zu entwickeln, mit deren Hilfe unerwünschte Wirkungen von Arzneimitteln früher und zuverlässiger erkannt werden können. Um die Vorhersage von Lebertoxizität in präklinischen Studien zu verbessern, wurden im Rahmen dieser Arbeit zwei wesentliche Ansätze gewählt: 1) die Evaluierung neuer Biomarker, durch die Lebertoxizität zuverlässiger und empfindlicher detektiert werden könnte und 2.) wirkmechanistische Untersuchungen mittels Toxcicogenomics für ein besseres Verständnis der zugrunde liegenden Mechanismen der Arzneimittel-induzierten Toxizität. Ein Ziel dieser Arbeit war, die Fähigkeit einiger neuer potenzieller Biomarker (NGAL, Thiostatin, Clusterin und PON1) zu bewerten, Arzmeimittel-induzierte Lebertoxizität in Ratten frühzeitig zu erkennen. Die Ergebnisse zeigen, dass PON1 und Clusterin infolge eines durch die verabreichten Arzneistoffkandidaten verursachten Leberschadens nicht konsistent verändert waren. Diese beiden Marker sind daher, verglichen mit bestehenden klinisch-chemischen Markern, nicht für eine sichere Vorhersage von Arzneistoff-induzierten Leberschäden geeignet. Bei Thiostatin und NGAL zeigte sich hingegen ein zeit- und dosisabhängiger Anstieg im Serum und Urin behandelter Tiere. Diese Veränderungen, die gut mit der mRNA Expression im Zielorgan übereinstimmten, korrelierten mit dem Schweregrad der Arzneistoff-induzierten Leberschäden. Die Analyse mittels ROC zeigte, Thiostatin im Serum, nicht aber NGAL, ein besserer Indikator für Arzneimittel-induzierte hepatobiliäre Schäden ist als die routinemäßig verwendeten klinische-chemischen Marker, wie z.B. die Leberenzyme ALP, ALT und AST. Thiostatin wird jedoch als Akute-Phase-Protein in einer Vielzahl von Geweben exprimiert und kann somit nicht spezifisch als Lebermarker betrachtet werden. Dennoch zeigen unsere Ergebnisse, dass Thiostatin als sensitiver, minimal-invasiver diagnostischer Marker für Entzündungsprozesse und Gewebeschäden eine sinnvolle Ergänzung in der präklinischen Testung auf Lebertoxizität darstellt. Im zweiten Teil dieser Arbeit wurde mittels RNA-Interferenz das pharmakologische Target des Arzneistoffkandidaten BAY16, der Glukagonrezeptor, auf mRNA-Ebene gehemmt und anhand von Genexpressionsanalysen untersucht, ob die pharmakologisch-bedingte Modulation des Glukagonrezeptors eine Rolle in der Toxizität von BAY16 spielt. Desweiteren sollten diese Arbeiten Aufschluss geben, welche molekularen Veränderungen auf die pharmakologische Wirkung des Arzneistoffs zurückzuführen sind, und daher für den Mechanismus der Toxizität möglicherweise wenig relevant sind. Während BAY16 in Konzentrationen von 75 µM starke zytotoxische Wirkungen aufwies, hatte die siRNA vermittelte Depletion des Glukagonrezeptors keinen Einfluss auf die Vitalität primärer Rattenhepatozyten. Daraus lässt sich ableiten, dass die Hepatotoxiziät von BAY16 in vitro und in vivo nicht mit der pharmakologischen Modulation des Glukagonrezeptors assoziiert ist. Diese Ergebnisse wurden durch die Tatsache gestützt, dass die meisten der durch BAY16 induzierten Genexpressionsveränderungen unabhängig von der pharmakologischen Modulation des Glucagonrezeptors auftraten. Diese beobachteten off-target-Effekte beinhalteten Veränderungen im Fremdstoffmetabolismus, oxidativer Stress, erhöhte Fettsäuresynthese und Veränderungen im Cholesterol- und Gallensäuremetabolismus. Obwohl Veränderungen in diesen molekularen Mechanismen zum Fortschreiten eines Leberschadens beitragen können, ist es anhand dieser Daten nicht möglich einen eindeutigen Mechanismus für die Toxizität von BAY16 abzuleiten. In dieser Arbeit konnte jedoch gezeigt werden, dass die Anwendung der siRNA-Technologie einen neuen methodischen Ansatz darstellt, um Mechanismen arzneimittelbedingter Toxizität besser verstehen zu können. N2 - The high failure rate of new drug candidates in preclinical or clinical studies due to hepatotoxicity represents a considerable problem in the drug development. Hence, there is an urgent need to develop new approaches for early and reliable prediction of drug-induced hepatotoxicity that enables a better identification of drug candidates with high potential for toxicity at early stages of drug development. Therefore, the aim of this work was to improve the prediction of drug-induced liver injury in preclinical studies through evaluation of more reliable and sensitive biomarkers of hepatotoxicity and a better understanding of the underlying mechanistic basis for drug-induced toxicity. First, the ability of a set of potential markers (NGAL, thiostatin, clusterin, PON1) to detect early signs of liver injury was assessed in rats treated with drug candidates that were dropped from further development, in part due to toxic adverse effects in the liver. In summary, PON1 and clusterin were not consistently altered in response to liver injury and thus provide no additive information to the traditional liver enzymes in detecting drug-induced hepatotoxicity. In contrast, thiostatin and NGAL were increased in serum and urine of treated animals in a time- and dose-dependent manner. These changes correlated well with mRNA expression in the target organ and generally reflected the onset and degree of drug-induced liver injury. Receiver-operating characteristics analyses supported serum thiostatin, but not NGAL, as a better indicator of drug-induced hepatobiliary injury than conventional clinical chemistry parameters, such as ALP, ALT and AST. Although thiostatin, an acute phase protein expressed in a range of tissues, may not be specific for liver injury, our results indicate that thiostatin may serve as a sensitive, minimally-invasive diagnostic marker of inflammation and tissue damage in preclinical safety assessment. In the second part of this work, combined application of genomics profiling technology and RNAi to inhibit the pharmacological target of a drug candidate BAY16, a glucagon receptor (GCGR) antagonist, was used to determine if interference with the pharmacological target plays a role in the toxic response to BAY16, and to narrow down those molecular changes that are associated with toxicity, and not the pharmacological action of BAY16. In contrast to Bay 16, which was found to be cytotoxic at concentrations of 75 µM, silencing of the glucagon receptor did not affect cell viability in primary rat hepatocytes. Thus, it can be concluded that hepatotoxicity of Bay 16 was not related to the drugs inhibitory effect on the glucagon receptor in vitro and in vivo. These findings were supported by the fact that most of BAY16-induced changes in gene expression occurred independently of the pharmacological modulation of GCGR. These off-target effects include altered xenobiotic metabolism, oxidative stress, increased fatty acid synthesis, and alterations in cholesterol and bile acid metabolic processes. Although it was not possible to draw a final conclusion about the mechanism of BAY16 hepatotoxicity, changes in these molecular mechanisms appear contribute to progression of hepatic injury. With regard to drug safety assessment in preclinical studies, the utilization of siRNA technology in vitro represents a new approach to improve mechanistic understanding of the nature of drug’s toxicity, being either chemically mediated or due to primary or secondary pharmacological mode of action. KW - Biomarker KW - Leber KW - Hepatotoxizität KW - Lebertoxizität KW - biomarker KW - liver KW - hepatotoxicity Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-69512 ER - TY - JOUR A1 - Aeschlimann, Martin A1 - Bauer, Michael A1 - Bayer, Daniela A1 - Brixner, Tobias A1 - Cunovic, Stefan A1 - Fischer, Alexander A1 - Melchior, Pascal A1 - Pfeiffer, Walter A1 - Rohmer, Martin A1 - Schneider, Christian A1 - Strüber, Christian A1 - Tuchscherer, Philip A1 - Voronine, Dimitri V. T1 - Optimal open-loop near-field control of plasmonic nanostructures N2 - Optimal open-loop control, i.e. the application of an analytically derived control rule, is demonstrated for nanooptical excitations using polarization-shaped laser pulses. Optimal spatial near-field localization in gold nanoprisms and excitation switching is realized by applying a shift to the relative phase of the two polarization components. The achieved near-field switching confirms theoretical predictions, proves the applicability of predefined control rules in nanooptical light–matter interaction and reveals local mode interference to be an important control mechanism. KW - Chemie Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75256 ER - TY - JOUR A1 - Agoston, Zsuzsa A1 - Li, Naixin A1 - Haslinger, Anja A1 - Wizenmann, Andrea A1 - Schulte, Dorothea T1 - Genetic and physical interaction of Meis2, Pax3 and Pax7 during dorsal midbrain development JF - BMC Developmental Biology N2 - Background: During early stages of brain development, secreted molecules, components of intracellular signaling pathways and transcriptional regulators act in positive and negative feed-back or feed-forward loops at the mid-hindbrain boundary. These genetic interactions are of central importance for the specification and subsequent development of the adjacent mid-and hindbrain. Much less, however, is known about the regulatory relationship and functional interaction of molecules that are expressed in the tectal anlage after tectal fate specification has taken place and tectal development has commenced. Results: Here, we provide experimental evidence for reciprocal regulation and subsequent cooperation of the paired-type transcription factors Pax3, Pax7 and the TALE-homeodomain protein Meis2 in the tectal anlage. Using in ovo electroporation of the mesencephalic vesicle of chick embryos we show that (i) Pax3 and Pax7 mutually regulate each other's expression in the mesencephalic vesicle, (ii) Meis2 acts downstream of Pax3/7 and requires balanced expression levels of both proteins, and (iii) Meis2 physically interacts with Pax3 and Pax7. These results extend our previous observation that Meis2 cooperates with Otx2 in tectal development to include Pax3 and Pax7 as Meis2 interacting proteins in the tectal anlage. Conclusion: The results described here suggest a model in which interdependent regulatory loops involving Pax3 and Pax7 in the dorsal mesencephalic vesicle modulate Meis2 expression. Physical interaction with Meis2 may then confer tectal specificity to a wide range of otherwise broadly expressed transcriptional regulators, including Otx2, Pax3 and Pax7. KW - dosage KW - quali-chick chimeras KW - drosophila embryo KW - neural crest KW - transcription activation KW - hindbrain boundary KW - isthmic oragnizer KW - sonic hedghog KW - expression KW - induction Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132626 VL - 12 IS - 10 ER - TY - THES A1 - Ahmad, Ruhel T1 - Neurogenesis from parthenogenetic human embryonic stem cells T1 - Neurogenese von parthenogenetischen humanen embryonalen Stammzellen N2 - Imprinted genes play important roles in brain development. As the neural developmental capabilities of human parthenogenetic embryonic stem cells (hpESCs) with only a maternal genome were not assessed in great detail, hence here the potential of hpESCs to differentiate into various neural subtypes was determined. In addition DNA methylation and expression of imprinted genes upon neural differentiation was also investigated. The results demonstrated that hpESC-derived neural stem cells (hpNSCs) showed expression of NSC markers Sox1, Nestin, Pax6, and Musashi1 (MS1), the silencing of pluripotency genes (Oct4, Nanog) and the absence of activation of neural crest (Snai2, FoxD3) and mesodermal (Acta1) markers. Moreover, confocal images of hpNSC cultures exhibited ubiquitous expression of NSC markers Nestin, Sox1, Sox2 and Vimentin. Differentiating hpNSCs for 28 days generated neural subtypes with neural cell type-specific morphology and expression of neuronal and glial markers, including Tuj1, NeuN, Map2, GFAP, O4, Tau, Synapsin1 and GABA. hpNSCs also responded to region-specific differentiation signals and differentiated into regional phenotypes such as midbrain dopaminergic- and motoneuron-type cells. hpESC-derived neurons showed typical neuronal Na+/K+ currents in voltage clamp mode, elicited multiple action potentials with a maximum frequency of 30 Hz. Cell depicted a typical neuron-like current pattern that responded to selective pharmacological blockers of sodium (tetrodotoxin) and potassium (tetraethylammonium) channels. Furthermore, in hpESCs and hpNSCs the majority of CpGs of the differentially methylated regions (DMRs) KvDMR1 were methylated whereas DMR1 (H19/Igf2 locus) showed partial or complete absence of CpG methylation, which is consistent with a parthenogenetic (PG) origin. Upon differentiation parent-of-origin-specific gene expression was maintained in hpESCs and hpNSCs as demonstrated by imprinted gene expression analyses. Together this shows that despite the lack of a paternal genome, hpNSCs are proficient in differentiating into glial- and neuron-type cells, which exhibit electrical activity similar to newly formed neurons. Moreover, maternal-specific gene expression and imprinting-specific DNA-methylation are largely maintained upon neural differentiation. hpESCs are a means to generate histocompatible and disease allele-free ESCs. Additionally, hpESCs are a unique model to study the influence of imprinting on neurogenesis. N2 - Imprinted Gene spielen eine wichtige Rolle bei der Gehirnentwicklung. Da das neurale Entwicklungspotenzial von hpESCs bisher noch nicht ausführlich untersucht wurde, war das Ziel dieser Arbeit das Differenzierungspotenzial von hpESCs zu verschiedenen neuralen Subtypen zu untersuchen. Außerdem wurden die DNA-Methylierung und Expression imprinted Gene in hpESCs während der neuralen Differenzierung analysiert. Die Ergebnisse zeigten, dass von hpESCs abgeleitete neurale Stammzellen (hpNSCs) die NSC-Marker Sox1, Nestin, Pax6 und Musashi1 (MS1) exprimierten, Pluripotenzmarker-Gene (Oct4, Nanog) abschalteten und keine Aktivierung von Markern der Neuralleistenzellen (Snai2, FoxD3) sowie dem mesodermalen Marker Acta1 stattfand. Immunfärbungen zeigten weiterhin, dass aus hpESCs abgeleitete Stammzellen die NSC-Marker Nestin, Sox1, Sox2 und Vimentin auf Proteinebene exprimierten. Durch gerichtete neurale Differenzierung für 28 Tage konnten aus hpESCs neurale Subtypen abgeleitet werden, die eine neurale Zelltyp-spezifische Morphologie aufweisen und positiv für neuronale und gliale Marker wie Tuj1, NeuN, Map2, GFAP, O4, Tau, Synapsin1 und GABA sind. Um aus hpNSCs dopaminerge und Motoneuronen abzuleiten, wurden während der Differenzierung Morphogene und trophische Faktoren zugegeben. Elektrophysiologische Analysen konnten zeigen, dass die in vitro differenzierten Neuronen, die von hpESCs abgeleitet wurden, für Neurone typische Na+/K+ Ströme sowie Aktionspotentiale (30 Hz) vorweisen ausbilden und auf ausgewählte pharmakologische Natrium- (Tetrodotoxin) und Kalium- (Tetraethylammonium) Kanal-Blocker reagierten. Desweiteren war der Großteil der CpGs von differentiell methylierten Regionen (DMRs) KvDMR1 in hpESCs und hpNSCs methyliert, während DMR1 (H19/Igf2 Locus) eine partiell oder komplett abwesende CpG-Methylierung zeigte, was dem parthenogenetischen Ursprung entspricht. Während der Differenzierung wurde die elternabhängige (parent-of-origin) spezifische Genexpression in hpESCs und hpNSCs aufrechterhalten, wie mit Genexpressionsanalysen imprinted Gene gezeigt werden konnte. In der Summe zeigen die hier dargestellten Ergebnisse, dass hpESCs, die kein paternales Genom besitzen, keine Beeinträchtigung im neuralen Differenzierungspotential zeigten und zu Gliazellen und Neurone differenziert werden konnten. Elektrophysiologische Analysen zeigten ferner, dass von hpESCs abgeleitete Neurone funktionell sind. Zudem wird die Expression maternal-spezifischer Gene und die Imprinting-spezifische DNA-Methylierung während der Differenzierung größtenteils aufrechterhalten. In der Summe stellen hpESCs ein einzigartiges Modell dar, um den Einfluss des Imprintings auf die Neurogenese zu untersuchen. KW - Embryonale Stammzelle KW - Neurogenese KW - Zelldifferenzierung KW - Stammzelle KW - human parthenogenetic stem cells KW - in vitro neural differentiation KW - human parthenogenetic neural stem cells KW - PG neurons KW - imprinting. Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75935 ER - TY - JOUR A1 - Ahmad, Ruhel A1 - Wolber, Wanja A1 - Eckardt, Sigrid A1 - Koch, Philipp A1 - Schmitt, Jessica A1 - Semechkin, Ruslan A1 - Geis, Christian A1 - Heckmann, Manfred A1 - Brüstle, Oliver A1 - McLaughlin, John K. A1 - Sirén, Anna-Leena A1 - Müller, Albrecht M. T1 - Functional Neuronal Cells Generated by Human Parthenogenetic Stem Cells JF - PLoS One N2 - Parent of origin imprints on the genome have been implicated in the regulation of neural cell type differentiation. The ability of human parthenogenetic (PG) embryonic stem cells (hpESCs) to undergo neural lineage and cell type-specific differentiation is undefined. We determined the potential of hpESCs to differentiate into various neural subtypes. Concurrently, we examined DNA methylation and expression status of imprinted genes. Under culture conditions promoting neural differentiation, hpESC-derived neural stem cells (hpNSCs) gave rise to glia and neuron-like cells that expressed subtype-specific markers and generated action potentials. Analysis of imprinting in hpESCs and in hpNSCs revealed that maternal-specific gene expression patterns and imprinting marks were generally maintained in PG cells upon differentiation. Our results demonstrate that despite the lack of a paternal genome, hpESCs generate proliferating NSCs that are capable of differentiation into physiologically functional neuron-like cells and maintain allele-specific expression of imprinted genes. Thus, hpESCs can serve as a model to study the role of maternal and paternal genomes in neural development and to better understand imprinting-associated brain diseases. KW - methylation KW - derivation KW - blastocysts KW - pluripotent KW - differentiation KW - lines KW - brain development KW - in-vitro KW - mice KW - specification Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130268 VL - 7 IS - 8 ER - TY - THES A1 - Akindeinde, Saheed Ojo T1 - Numerical Verification of Optimality Conditions in Optimal Control Problems T1 - Numerischen Verifizierung von Optimalitätsbedingungen für Optimalsteurungsprobleme N2 - This thesis is devoted to numerical verification of optimality conditions for non-convex optimal control problems. In the first part, we are concerned with a-posteriori verification of sufficient optimality conditions. It is a common knowledge that verification of such conditions for general non-convex PDE-constrained optimization problems is very challenging. We propose a method to verify second-order sufficient conditions for a general class of optimal control problem. If the proposed verification method confirms the fulfillment of the sufficient condition then a-posteriori error estimates can be computed. A special ingredient of our method is an error analysis for the Hessian of the underlying optimization problem. We derive conditions under which positive definiteness of the Hessian of the discrete problem implies positive definiteness of the Hessian of the continuous problem. The results are complemented with numerical experiments. In the second part, we investigate adaptive methods for optimal control problems with finitely many control parameters. We analyze a-posteriori error estimates based on verification of second-order sufficient optimality conditions using the method developed in the first part. Reliability and efficiency of the error estimator are shown. We illustrate through numerical experiments, the use of the estimator in guiding adaptive mesh refinement. N2 - Diese Arbeit widmet sich der numerischen Verifizierung von Optimalitaetsbedingungen fuer nicht konvexe Optimalsteuerungsprobleme. Im ersten Teil beschaeftigen wir uns mit der a-posteriori Ueberpruefung von hinreichenden Optimalitaetskriterien. Es ist bekannt, dass der Nachweis solcher Bedingungen fuer allgemeine nicht konvexe Optimierungsproblemem mit Nebenbedingungen in Form von partiellen Differentialgleichungen sehr schwierig ist. Wir stellen eine Methode vor, um die hinreichenden Bedingungen zweiter Ordnung fuer eine allgemeine Problemklasse zu testen. Falls die vorgeschlagene Strategie bestaetigt, dass diese Bedingungen erfuellt sind, koennen a-posteriori Fehlerschaetzungen berechnet werden. Ein wesentlicher Bestandteil unserer Methode ist eine Fehleranalyse fuer die Hessematrix des zugrunde liegenden Optimierungsproblems. Es werden Bedingungen hergeleitet, unter denen die positive Definitheit der Hessematrix des diskreten Problems die positive Definitheit der Hessematrix fuer das kontinuierliche Problem nach sich zieht. Diese Ergebnisse werden durch numerische Experimente ergaenzt. Im zweiten Teil untersuchen wir adaptive (Diskretisierungs-)methoden fuer Optimalsteuerungsprobleme mit endlich vielen Kontrollparametern. Basierend auf dem Nachweis hinreichender Optimalitaetsbedingungen zweiter Ordnung analysieren wir a posteriori Fehlerschaetzungen. Dies geschieht unter der Nutzung der Resultate des ersten Teils der Arbeit. Es wird die Zuverlaessigkeit und Effizienz des Fehlerschaetzers bewiesen. Mittels weiterer numerischer Experimente illustrieren wir, wie der Fehlerschaetzer zur Steuerung adaptiver Gitterverfeinerung eingesetzt werden kann. KW - Optimale Kontrolle KW - Nichtkonvexe Optimierung KW - Numerisches Verfahren KW - non-convex optimal control problems KW - sufficient optimality conditions KW - a-posteriori error estimates KW - numerical approximations KW - adaptive refinement Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-76065 ER - TY - JOUR A1 - Alb, Miriam A1 - Sie, Christopher A1 - Adam, Christian A1 - Chen, Suzie A1 - Becker, Jürgen C. A1 - Schrama, David T1 - Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma JF - Cancer Immunology, Immunotherapy N2 - Grm1-transgenic mice spontaneously develop cutaneous melanoma. This model allowed us to scrutinize the generic immune responses over the course of melanoma development. To this end, lymphocytes obtained from spleens, unrelated lymph nodes and tumor-draining lymph nodes of mice with no evidence of disease, and low or high tumor burden were analyzed ex vivo and in vitro. Thereby, we could demonstrate an increase in the number of activated CD4\(^+\) and CD8+ lymphocytes in the respective organs with increasing tumor burden. However, mainly CD4\(^+\) T cells, which could constitute both T helper as well as immunosuppressive regulatory T cells, but not CD8\(^+\) T cells, expressed activation markers upon in vitro stimulation when obtained from tumor-bearing mice. Interestingly, these cells from tumor-burdened animals were also functionally hampered in their proliferative response even when subjected to strong in vitro stimulation. Further analyses revealed that the increased frequency of regulatory T cells in tumor-bearing mice is an early event present in all lymphoid organs. Additionally, expression of the immunosuppressive cytokines TGF-β1 and IL-10 became more evident with increased tumor burden. Notably, TGF-β1 is strongly expressed in both the tumor and the tumor-draining lymph node, whereas IL-10 expression is more pronounced in the lymph node, suggesting a more complex regulation of IL-10. Thus, similar to the situation in melanoma patients, both cytokines as well as cellular immune escape mechanisms seem to contribute to the observed immunosuppressed state of tumor-bearing grm1-transgenic mice, suggesting that this model is suitable for preclinical testing of immunomodulatory therapeutics. KW - regulatory T cell KW - melanoma KW - immune suppression KW - tumor-draining lymph node Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125096 VL - 61 IS - 12 ER - TY - JOUR A1 - Albert-Weissenberger, Christiane A1 - Stetter, Christian A1 - Meuth, Sven G. A1 - Göbel, Kerstin A1 - Bader, Michael A1 - Sirén, Anna-Leena A1 - Kleinschnitz, Christoph T1 - Blocking of Bradykinin Receptor B1 Protects from Focal Closed Head Injury in Mice by Reducing Axonal Damage and Astroglia Activation JF - Journal of Cerebral Blood Flow and Metabolism N2 - The two bradykinin receptors B1R and B2R are central components of the kallikrein–kinin system with different expression kinetics and binding characteristics. Activation of these receptors by kinins triggers inflammatory responses in the target organ and in most situations enhances tissue damage. We could recently show that blocking of B1R, but not B2R, protects from cortical cryolesion by reducing inflammation and edema formation. In the present study, we investigated the role of B1R and B2R in a closed head model of focal traumatic brain injury (TBI; weight drop). Increased expression of B1R in the injured hemispheres of wild-type mice was restricted to the later stages after brain trauma, i.e. day 7 (P<0.05), whereas no significant induction could be observed for the B2R (P>0.05). Mice lacking the B1R, but not the B2R, showed less functional deficits on day 3 (P<0.001) and day 7 (P<0.001) compared with controls. Pharmacological blocking of B1R in wild-type mice had similar effects. Reduced axonal injury and astroglia activation could be identified as underlying mechanisms, while inhibition of B1R had only little influence on the local inflammatory response in this model. Inhibition of B1R may become a novel strategy to counteract trauma-induced neurodegeneration. KW - R-715 KW - kinin receptors KW - closed head injury KW - β-APP KW - astrocytes KW - TNF-α Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125903 VL - 32 IS - 9 ER - TY - JOUR A1 - Albert-Weißenberger, Christiane A1 - Várrallyay, Csanád A1 - Raslan, Furat A1 - Kleinschnitz, Christoph A1 - Sirén, Anna-Leena T1 - An experimental protocol for mimicking pathomechanisms of traumatic brain injury in mice N2 - Traumatic brain injury (TBI) is a result of an outside force causing immediate mechanical disruption of brain tissue and delayed pathogenic events. In order to examine injury processes associated with TBI, a number of rodent models to induce brain trauma have been described. However, none of these models covers the entire spectrum of events that might occur in TBI. Here we provide a thorough methodological description of a straightforward closed head weight drop mouse model to assess brain injuries close to the clinical conditions of human TBI. KW - Medizin KW - closed head injury KW - traumatic brain injury KW - neurobehavioural deficits KW - astrocyte KW - microglia KW - neurons Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75368 ER - TY - THES A1 - Alcantarino Menescal, Luciana T1 - In vivo characterization of genetic factors involved in Xmrk driven melanoma formation in Medaka (Oryzias latipes): a closer look at braf, Stat5 and c-myc T1 - In vivo Charakterisierung genetischer Faktoren mit Einfluss auf Xmrk induzierte Melanome in Medaka (Oryzias latipes): Untersuchung von braf, Stat5 und c-myc. N2 - Melanoma arises from the malignant transformation of melanocytes and is one of the most aggressive forms of human cancer. In fish of the genus Xiphophorus, melanoma development, although very rarely, happens spontaneously in nature and can be induced by interspecific crossing. The oncogenic receptor tyrosine kinase, Xmrk, is responsible for melanoma formation in these fishes. Since Xiphophorus are live-bearing fishes and therefore not compatible with embryonic manipulation and transgenesis, the Xmrk melanoma model was brought to the medaka (Oryzias latipes) system. Xmrk expression under the control of the pigment cell specific mitf promoter leads to melanoma formation with 100% penetrance in medaka. Xmrk is an orthologue of the human epidermal growth factor receptor (EGFR) and activates several downstream signaling pathways. Examples of these pathways are the direct phosphorylation of BRAF and Stat5, as well as the enhanced transcription of C-myc. BRAF is a serine-threonine kinase which is found mutated at high frequencies in malignant melanomas. Stat5 is a transcription factor known to be constitutively activated in fish melanoma. C-myc is a transcription factor that is thought to regulate the expression of approximately 15% of all human genes and is involved in cancer progression of a large number of different tumors. To gain new in vivo information on candidate factors known to be involved in melanoma progression, I identified and analysed BRAF, Stat5 and C-myc in the laboratory fish model system medaka. BRAF protein motifs are highly conserved among vertebrates and the results of this work indicate that its function in the MAPK signaling is maintained in medaka. Transgenic medaka lines carrying a constitutive active version of BRAF (V614E) showed more pigmented skin when compared to wild type. Also, some transiently expressing BRAF V614E fishes showed a disrupted eye phenotype. In addition, I was able to identify two Stat5 copies in medaka, named Stat5ab/a and Stat5ab/b. Sequence analysis revealed a higher similarity between both Stat5 sequences when compared to either human Stat5a or Stat5b. This suggests that the two Stat5 copies in medaka arose by an independent duplication processes. I cloned these two Stat5 present in medaka, produced constitutive active and dominant negative gene versions and successfully established transgenic lines carrying each version under the control of the MITF promoter. These lines will help to elucidate questions that are still remaining in Stat5 biology and its function in melanoma progression, like the role of Stat5 phosphorylation on tumor invasiveness. In a third project during my PhD work, I analysed medaka C-myc function and indentified two copies of this gene in medaka, named c-myc17 and c-myc20, according to the chromosome where they are located. I produced conditional transgenic medaka lines carrying the c-myc17 gene coupled to the hormone binding domain of the estrogen receptor to enable specific transgene activation at a given time point. Comparable to human C-myc, medaka C-myc17 is able to induce proliferation and apoptosis in vivo after induction. Besides that, C-myc17 long-term activation led to liver hyperplasia. In summary, the medaka models generated in this work will be important to bring new in vivo information on genes involved in cancer development. Also, the generated transgenic lines can be easily crossed to the melanoma developing Xmrk medaka lines, thereby opening up the possibility to investigate their function in melanoma progression. Besides that, the generated medaka fishes make it possible to follow the whole development of melanocytes, since the embryos are transparent and can be used for high throughput chemical screens. N2 - Melanome entstehen durch die krankhafte Transformation von Melanozyten und sind eine der aggressivsten Krebsarten beim Menschen. In Fischen der Gattung Xiphophorus können, wenn auch sehr selten, spontan Melanome entstehen oder durch spezielle Artenkreuzungen induziert werden. Grundlage für das Entstehen der Melanome in diesen Fischen ist die Rezeptortyrosinkinase Xmrk. Da alle Xiphophorus-Arten lebendgebärend sind und keine Manipulationen an Embryonen vorgenommen werden können, wurde ein Xmrk Melanommodel für Medaka (Oryzias latipes) etabliert. Die Expression von Xmrk in Pigmentzellen dieser Fischart resultiert mit 100%iger Penetranz in Melanomen. Das Xmrk ist ein Ortholog des menschlichen „epidermal growth factor“ (EGFR) und aktiviert verschiedene nachgeschaltete Signalwege. Beispiele für diese Aktivierungen sind die Phosphorylierung von BRAF, Stat5 und die erhöhte Expression von c-myc. BRAF ist eine Serin-Threoninkinase, welche oft in malignen Melanomen mutiert ist. Stat5 ist ein Transkriptionsfaktor, welcher dauerhaft in Fischtumoren aktiviert ist. C-myc ist ein Transkriptionsfaktor, welcher etwa 15% aller menschlichen Gene sowie die Entstehung vieler menschlicher Tumore reguliert. Um neue Einsichten in die Funktion der Kanidatengene im Prozess der Melanomentstehung in vivo zu erlangen, habe ich Orthologe von BRAF, Stat5 und C-myc bei Medaka identifiziert und analysiert. Die Domänen des BRAF Proteins sind hoch konserviert in allen Vertebraten. Weiterhin deuten die Ergebnisse meiner Arbeit auf eine Beibehaltung der Funktionen im MAPK Signalweg hin. Transgene Medakalinien, welche eine dauerhaft aktive Version des BRAF Gens (V614E) exprimieren, weisen einerseits eine stärkere Hautpigmentierung auf. Weiterhin treten in diesen Fischen Veränderungen der Augen auf. In einem weiteren Projekt meiner Arbeit gelang es mir, zwei Kopien des Stat5 Gens im Medaka zu identifizieren, Stat5ab/a und Stat5ab/b. Sequenzanalysen zeigten eine höhere Übereinstimmung zwischen den beiden Genkopien, als zwischen denen von Medaka und Menschen. Dieses Ergebnis deutet darauf hin, dass die beiden Medaka Gene durch eine unabhängige Duplikation entstanden. In meiner Arbeit habe ich beide Gene des Medakas kloniert und jeweils eine konstitutiv aktive und eine dominant negative Version der Gene hergestellt. Weiterhin konnte ich erfolgreich für jede Genversion eine transgene Medakalinie etablieren, welche die verschiedenen Genvarianten unter der Kontrolle des pigmentzellspezifischen Promoters des mitf Gens exprimieren. Diese Linien werden in Zukunft helfen, den Einfluss von Stat5 Signalen auf den Prozess der Melanomverbreitung und dessen Invasivität zu erklären. In einem dritten Projekt meiner Doktorarbeit untersuchte ich das Vorkommen und die Funktion der C-myc Gene des Medakas. Ich konnte zwei Genkopien identifizieren, c-myc17 und c-myc20, welche auf unterschiedlichen Chromosomen lokalisiert sind. Ich konnte induzierbare, stabil transgene Linien herstellen, welche ein Fusionsprotein aus C-myc17 und der Hormonbindungsdomäne des Östrogenrezeptors von Maus exprimiert. Diese Linie ermöglichte eine induzierbare Aktivität des Transgens. Vergleichbar zum menschlichen MYC ist C-myc17 fähig, nach Aktivierung Proliferation und Apoptose in vivo auszulösen. Dauerhafte Aktivierung über einen längeren Zeitraum führt in diesen Linien zu Hyperplasie in Leber. Die verschiedenen Fischmodelle, die während dieser Arbeit generiert wurden, werden essentiell sein, um neue Einsichten in die Rolle diese Faktoren während der Krebsentwicklung in vivo zu erlangen. Weiterhin ermöglichen diese transgenen Linien durch einfaches Auskreuzen auf Xmrk Linien, deren Einfluss auf die Verbreitung von Melanomen zu untersuchen. Letztendlich sind mit diesen Linien auch Untersuchungen der Entwicklung von Pigmentzellen über Zeit möglich, da die Embryonen transparent sind und sich für chemisches Hochdurchsatz-Screening eignen. KW - Japankärpfling KW - Melanom KW - Myc KW - Molekulargenetik KW - melanoma KW - medaka KW - BRAF KW - Stat5 KW - c-myc KW - melanoma KW - medaka KW - BRAF KW - Stat5 KW - c-myc Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-70762 ER - TY - JOUR A1 - Amich, Jorge A1 - Krappmann, Sven T1 - Deciphering metabolic traits of the fungal pathogen Aspergillus fumigatus: redundancy vs. essentiality JF - Frontiers in Microbiology N2 - Incidence rates of infections caused by environmental opportunistic fungi have risen over recent decades. Aspergillus species have emerged as serious threat for the immunecompromised, and detailed knowledge about virulence-determining traits is crucial for drug target identification. As a prime saprobe, A. fumigatus has evolved to efficiently adapt to various stresses and to sustain nutritional supply by osmotrophy, which is characterized by extracellular substrate digestion followed by efficient uptake of breakdown products that are then fed into the fungal primary metabolism. These intrinsic metabolic features are believed to be related with its virulence ability. The plethora of genes that encode underlying effectors has hampered their in-depth analysis with respect to pathogenesis. Recent developments in Aspergillus molecular biology allow conditional gene expression or comprehensive targeting of gene families to cope with redundancy. Furthermore, identification of essential genes that are intrinsically connected to virulence opens accurate perspectives for novel targets in antifungal therapy. KW - Aspergillus fumigatus KW - aspergillosis KW - virulence KW - conditional promoter replacement KW - nutrients KW - gene family targeting Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123669 VL - 3 ER - TY - THES A1 - Aminake, Makoah Nigel T1 - Towards malaria combination therapy: Characterization of hybrid molecules for HIV/malaria combination therapy and of thiostrepton as a proteasome-targeting antibiotic with a dual mode of action T1 - Die Entwicklung von Malaria-Kombinationstherapien: Die Charakterisierung von Hybridmolekülen für eine HIV/Malaria-Kombinationstherapie und von Thiostrepton als ein gegen das Proteasom-gerichtetes Antibiotikum mit dualem Wirkmodus N2 - Malaria and HIV are among the most important global health problems of our time and together are responsible for approximately 3 million deaths annually. These two diseases overlap in many regions of the world including sub-Saharan Africa, Southeast Asia and South America, leading to a higher risk of co-infection. In this study, we generated and characterized hybrid molecules to target P. falciparum and HIV simultaneously for a potential HIV/malaria combination therapy. Hybrid molecules were synthesized by covalent fusion between azidothymidine (AZT) and dihydroartemisinin (DHA), tetraoxane or chloroquine (CQ); and a small library was generated and tested for antiviral and antimalarial activity. Our data suggest that dihyate is the most potent molecule in vitro, with antiplasmodial activity comparable to that of DHA (IC50 = 26 nM, SI > 3000), a moderate activity against HIV (IC50 = 2.9 µM; SI > 35) and safe to HeLa cells at concentrations used in the assay (CC50 > 100 µM). Pharmacokinetic studies further revealed that dihyate is metabolically unstable and is cleaved following an O-dealkylation once in contact with cytochrome P450 enzymes. The later further explains the uneffectiveness of dihyate against the CQ-sensitive P. berghei N strain in mice when administered by oral route at 20 mg/kg. Here, we report on a first approach to develop antimalarial/anti-HIV hybrid molecules and future optimization efforts will aim at producing second generation hybrid molecules to improve activity against HIV as well as compound bioavailability. With the emergence of resistant parasites against all the counterpart drugs of artemisinin derivatives used in artemisinin based combination therapies (ACTs), the introduction of antibiotics in the treatment of malaria has renewed interest on the identification of antibiotics with potent antimalarial properties. In this study we also investigated the antiplasmodial potential of thiostrepton and derivatives, synthesized using combinations of tail truncation, oxidation, and addition of lipophilic thiols to the terminal dehydroamino acid. We showed that derivatives SS231 and SS234 exhibit a better antiplasmodial activity (IC50 = 1 µM SI > 59 and SI > 77 respectively) than thiostrepton (IC50 = 8.95 µM, SI = 1.7). The antiplasmodial activity of these derivatives was observed at concentrations which are not hemolytic and non-toxic to human cell lines. Thiostrepton and derivatives appeared to exhibit transmission blocking properties when administered at their IC50 or IC90 concentrations and our data also showed that they attenuate proteasome activity of Plasmodium, which resulted in an accumulation of ubiquitinated proteins after incubation with their IC80 concentrations. Our results indicate that the parasite’s proteasome could be an attractive target for therapeutic intervention. In this regard, thiostrepton derivatives are promising candidates by dually acting on two independent targets, the proteasome and the apicoplast, with the capacity to eliminate both intraerythrocytic asexual and transmission stages of the parasite. To further support our findings, we evaluated the activity of a new class of antimalarial and proteasome inhibitors namely peptidyl sulfonyl fluorides on gametocyte maturation and analogues AJ34 and AJ38 were able to completely suppress gametocytogenesis at IC50 concentrations (0.23 µM and 0.17 µM respectively) suggesting a strong transmission blocking potential. The proteasome, a major proteolytic complex, responsible for the degradation and re-cycling of non-functional proteins has been studied only indirectly in P. falciparum. In addition, an apparent proteasome-like protein with similarity to bacterial ClpQ/hslV threonine-peptidases was predicted in the parasite. Antibodies were generated against the proteasome subunits alpha type 5 (α5-SU), beta type 5 (β5-SU) and pfhslV in mice and we showed that the proteasome is expressed in both sexual and asexual blood stages of P. falciparum, where they localize in the nucleus and in the cytoplasm. However, expression of PfhslV was only observed in trophozoites and shizonts. The trafficking of the studied proteasome subunits was further investigated by generating parasites expressing GFP tagged proteins. The expression of α5-SU-GFP in transgenic parasite appeared to localize abundantly in the cytoplasm of all blood stages, and no additional information was obtained from this parasite line. In conclusion, our data highlight two new tools towards combination therapy. Hybrid molecules represent promising tools for the cure of co-infected individuals, while very potent antibiotics with a wide scope of activities could be useful in ACTs by eliminating resistant parasites and limiting transmission of both, resistances and disease. N2 - Malaria und HIV gehören zu den wichtigsten weltweiten Gesundheitsproblemen unserer Zeit und verursachen jährlich zusammen fast drei Millionen Todesfälle. Das Verbreitungsgebiet beider Krankheit überschneidet sich in vielen Weltregionen wie Afrika südlich der Sahara, Südostasien und Südamerika, was zu einem erhöhten Risiko für Koinfektionen führt. Während der vorliegenden Arbeit stellten wir Hybridmoleküle her und charakterisierten diese in Bezug auf ihre gleichzeitige Wirksamkeit gegen P. falciparum und HIV mit dem Ziel einer möglichen Kombinationstherapie gegen beide Krankheiten. Diese Hybridmoleküle wurden durch kovalente Verbindung von Azidothymidin (AZT) mit Dihydroartemisinin (DHA), Tetraoxan und Chloroquin (CQ) hergestellt. Die dabei hergestellte kleine Molekülsammlung wurde auf antivirale Wirkung und Wirkung gegen Malaria getestet. In vitro ist, gemäß unserer Daten, Dihyate das wirksamste Molekül, mit einer dem DHA vergleichbaren Wirksamkeit gegen Plasmodium (IC50 = 26 nM, SI > 3000), einer mittelmäßigen Wirksamkeit gegen HIV (IC50 = 2.9 µM; SI > 35) und keiner Wirkung auf HeLa-Zellen bei den im Versuch verwendeten Konzentrationen (CC50 > 100 µM). Weiterhin ergaben pharmakokinetische Studien, dass Dihyate metabolisch instabil ist und nach einer O-Dealkylierung gespalten wird, sobald es in Kontakt mit Cytochrom P450 Enzymen kommt. Dies erklärt auch die Unwirksamkeit von Dihyate gegen dem CQ-sensitiven P. berghei N Stamm im Mausversuch bei oraler Gabe von 20mg/kg. Wir berichten hier von einem ersten Ansatz Hybridmoleküle gegen Malaria/ HIV zu entwickeln. Zukünftige Verbesserungen werden darauf abzielen Hybridmoleküle der zweiten Generation herzustellen um sowohl die Wirksamkeit gegen HIV als auch die Bioverfügbarkeit zu verbessern. Auf Grund der Entwicklung von Resistenzen gegenüber sämtliche Substanzen, die zusammen mit Artemisinin in Kombinationstherapien genutzt werden, hat die Verwendung von Antibiotika bei der Behandlung der Malaria das Interesse daran neu geweckt, Antibiotika mit starker Wirksamkeit gegenüber Plasmodium aufzuspüren. Während der vorliegenden Studie untersuchten wir die Wirksamkeit von Thiostrepton und seinen Derivaten gegenüber Plasmodium. Diese Derivate wurden durch Kombinationen von Verkürzung der Seitenkette, Oxidation und der Anbringung von lipophilen Thiolen an die endständige Dehydroaminosäure hergestellt. Wir konnten zeigen, dass die Derivate SS231 und SS234 (IC50 = 1 µM SI > 59 und SI > 77) eine bessere Wirksamkeit gegen Plasmodium besitzen als Thiostrepton (IC50 = 8.95 µM, SI = 1.7). Diese Wirksamkeit konnte bei Konzentrationen beobachtet werden, die nicht hämolytisch sind und ungiftig gegenüber menschlichen Zelllinien. Thiostrepton und seine Derivate zeigten transmissionsblockierende Eigenschaften, wenn sie in Konzentrationen, die ihren IC50- oder IC90-Werten entsprachen, eingesetzt wurden. Unsere Daten zeigen auch, dass diese Substanzen die Aktivität des Proteasoms von Plasmodium abschwächen, was zu einer Anreicherung von ubiquitinierten Proteinen führte, wenn die Parasiten mit den Substanzen in IC80-Konzentrationen inkubiert wurden. Unsere Ergebnisse sprechen dafür, dass das Proteasom ein attraktives Ziel für therapeutische Maßnahmen sein kann. In diesem Zusammenhang sind die Derivate des Thiostreptons vielversprechende Kandidaten, da sie gleichzeitig an zwei unabhängigen Zielstrukturen angreifen, dem Proteasom und dem Apicoplasten und die Fähigkeit besitzen, sowohl die asexuellen Blutstadien als auch diejenigen Blutstadien, die für die Weitergabe des Parasiten verantwortlich sind, zu beseitigen. Um unsere Ergebnisse weiter zu untermauern, untersuchten wir die Wirkung von Peptidyl-Sulfonyl-Fluoriden, einer neuen Klasse von Substanzen mit Wirksamkeit gegen Malaria und hemmender Wirkung gegenüber dem Proteasom auf die Reifung von Gametozyten. Die Substanzen AJ34 und AJ38 unterdrückten die Bildung von Gametozyten vollständig, wenn sie in Konzentrationen, die ihren IC50-Werten (0.23 µM und 0.17 µM) entsprachen, eingesetzt wurden. Dies spricht für ein starkes transmissionsblockierendes Potential dieser Substanzen. Das Proteasom, ein bedeutender proteinabbauender Komplex, der für den Abbau und die Wiedergewinnung nicht funktioneller Proteine verantwortlich ist, wurde bisher nur indirekt in P. falciparum untersucht. Zusätzlich wurde die Existenz eines, dem Proteasom-ähnlichen, Proteins mit Ähnlichkeiten zu bakteriellen ClpQ/hslV Threonin-Peptidasen in Plasmodium vermutet. Gegen die Untereinheiten alpha 5 (α5-SU), beta 5 (β5-SU) und gegen pfhslV wurden in Mäusen Antikörper generiert. Mit diesen konnten wir zeigen, dass das Proteasom sowohl in den asexuellen als auch in den sexuellen Blutstadien von P. falciparum exprimiert wird und im Zellkern und im Zytoplasma lokalisiert sind. Die Expression von PfhslV konnte jedoch nur in Trophozoiten und Schizonten beobachtet werden. Der Transport der Proteasomuntereinheiten wurde weiterhin durch die Herstellung von transgenen Parasiten, die GFP-markierte Proteine bilden, untersucht. Die Expression von α5-SU-GFP in transgenen Parasiten schien im Zytoplasma aller Blutstadien lokalisiert zu sein, wobei durch diese Parasiten keine zusätzlichen Informationen gewonnen werden konnten. Zusammengefasst sprechen unsere Daten für zwei neue Werkzeuge für Kombinationstherapien. Hybridmoleküle sind vielversprechende Werkzeuge zur Heilung von gleichzeitig mit Malaria und HIV infizierten Patienten. Sehr wirksame Antibiotika mit einem breiten Wirkungsspektrum könnten in Artemisinin-Kombinationstherapien nützlich werden, wenn es darum geht, resistente Parasiten zu beseitigen und die Übertragung sowohl der Resistenz als auch der Krankheit zu verringern. KW - Malaria KW - HIV KW - Thiostrepton KW - Arzneimitteldesign KW - Malaria KW - HIV KW - co-infection KW - drug KW - screening KW - hybrid KW - proteasome KW - thiostrepton Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-71841 ER - TY - JOUR A1 - Angheloiu, George O. A1 - Hänscheid, Heribert A1 - Wen, Xiaoyan A1 - Capponi, Vincent A1 - Anderson, William D. A1 - Kellum, John A. T1 - Experimental first-pass method for testing and comparing sorbent polymers used in the clearance of iodine contrast materials JF - Blood Purification N2 - Background: Sorbents have been shown to adsorb iodinated radiocontrast media. Objective: In this study we describe a simple method to compare various sorbents in terms of capacity to adsorb radiocontrast media. Methods: Iodixanol solution was injected into columns filled with three types of sorbent at filtration velocities of increasing magnitude. Two variables of interest – contrast removal rate and matched iodine retention (MIR) – were calculated to measure the adsorption efficiency and the mass of contrast iodine adsorbed versus sorbent used, respectively. Results: The highest contrast removal and MIR for Porapak Q, CST 401 and Amberlite XAD4 were 41, 38 and 16% (p = 0.22 and 0.0005 for comparisons between Porapak Q-CST 401 and CST 401-Amberlite XAD4) and 0.060, 0.055 and 0.024, respectively (p = 0.18 and 0.0008). Extrapolation to a clinical scenario may suggest that removal of 8 ml iodixanol could be achieved by masses of sorbents of 43, 47 and 107 g, respectively. Conclusion: In this study we set a benchmark for comparing the radiocontrast-adsorbing efficiency of polymer sorbents during first-pass experiments, using a readily available methodology. KW - adsorption KW - acute renal failure KW - sorbents KW - iodine contrast Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-199118 SN - 0253-5068 SN - 1421-9735 N1 - Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. VL - 34 IS - 1 ER - TY - JOUR A1 - Antoniou, Antonis C. A1 - Kuchenbaecker, Karoline B. A1 - Soucy, Penny A1 - Beesley, Jonathan A1 - Chen, Xiaoqing A1 - McGuffog, Lesley A1 - Lee, Andrew A1 - Barrowdale, Daniel A1 - Healey, Sue A1 - Sinilnikova, Olga M. A1 - Caligo, Maria A. A1 - Loman, Niklas A1 - Harbst, Katja A1 - Lindblom, Annika A1 - Arver, Brita A1 - Rosenquist, Richard A1 - Karlsson, Per A1 - Nathanson, Kate A1 - Domchek, Susan A1 - Rebbeck, Tim A1 - Jakubowska, Anna A1 - Lubinski, Jan A1 - Jaworska, Katarzyna A1 - Durda, Katarzyna A1 - Zlowowcka-Perłowska, Elżbieta A1 - Osorio, Ana A1 - Durán, Mercedes A1 - Andrés, Raquel A1 - Benítez, Javier A1 - Hamann, Ute A1 - Hogervorst, Frans B. A1 - van Os, Theo A. A1 - Verhoef, Senno A1 - Meijers-Heijboer, Hanne E. J. A1 - Wijnen, Juul A1 - Garcia, Encarna B. Gómez A1 - Ligtenberg, Marjolijn J. A1 - Kriege, Mieke A1 - Collée, Margriet A1 - Ausems, Margreet G. E. M. A1 - Oosterwijk, Jan C. A1 - Peock, Susan A1 - Frost, Debra A1 - Ellis, Steve D. A1 - Platte, Radka A1 - Fineberg, Elena A1 - Evans, D. Gareth A1 - Lalloo, Fiona A1 - Jacobs, Chris A1 - Eeles, Ros A1 - Adlard, Julian A1 - Davidson, Rosemarie A1 - Cole, Trevor A1 - Cook, Jackie A1 - Paterson, Joan A1 - Douglas, Fiona A1 - Brewer, Carole A1 - Hodgson, Shirley A1 - Morrison, Patrick J. A1 - Walker, Lisa A1 - Rogers, Mark T. A1 - Donaldson, Alan A1 - Dorkins, Huw A1 - Godwin, Andrew K. A1 - Bove, Betsy A1 - Stoppa-Lyonnet, Dominique A1 - Houdayer, Claude A1 - Buecher, Bruno A1 - de Pauw, Antoine A1 - Mazoyer, Sylvie A1 - Calender, Alain A1 - Léoné, Mélanie A1 - Bressac-de Paillerets, Brigitte A1 - Caron, Olivier A1 - Sobol, Hagay A1 - Frenay, Marc A1 - Prieur, Fabienne A1 - Ferrer, Sandra Fert A1 - Mortemousque, Isabelle A1 - Buys, Saundra A1 - Daly, Mary A1 - Miron, Alexander A1 - Terry, Mary Beth A1 - Hopper, John L. A1 - John, Esther M. A1 - Southey, Melissa A1 - Goldgar, David A1 - Singer, Christian F. A1 - Fink-Retter, Anneliese A1 - Muy-Kheng, Tea A1 - Geschwantler Kaulich, Daphne A1 - Hansen, Thomas V. O. A1 - Nielsen, Finn C. A1 - Barkardottir, Rosa B. A1 - Gaudet, Mia A1 - Kirchhoff, Tomas A1 - Joseph, Vijai A1 - Dutra-Clarke, Ana A1 - Offit, Kenneth A1 - Piedmonte, Marion A1 - Kirk, Judy A1 - Cohn, David A1 - Hurteau, Jean A1 - Byron, John A1 - Fiorica, James A1 - Toland, Amanda E. A1 - Montagna, Marco A1 - Oliani, Cristina A1 - Imyanitov, Evgeny A1 - Isaacs, Claudine A1 - Tihomirova, Laima A1 - Blanco, Ignacio A1 - Lazaro, Conxi A1 - Teulé, Alex A1 - Del Valle, J. A1 - Gayther, Simon A. A1 - Odunsi, Kunle A1 - Gross, Jenny A1 - Karlan, Beth Y. A1 - Olah, Edith A1 - Teo, Soo-Hwang A1 - Ganz, Patricia A. A1 - Beattie, Mary S. A1 - Dorfling, Cecelia M. A1 - Jansen van Rensburg, Elizabeth A1 - Diez, Orland A1 - Kwong, Ava A1 - Schmutzler, Rita K. A1 - Wappenschmidt, Barbara A1 - Engel, Christoph A1 - Meindl, Alfons A1 - Ditsch, Nina A1 - Arnold, Norbert A1 - Heidemann, Simone A1 - Niederacher, Dieter A1 - Preisler-Adams, Sabine A1 - Gadzicki, Dorothea A1 - Varon-Mateeva, Raymonda A1 - Deissler, Helmut A1 - Gehrig, Andrea A1 - Sutter, Christian A1 - Kast, Karin A1 - Fiebig, Britta A1 - Schäfer, Dieter A1 - Caldes, Trinidad A1 - de la Hoya, Miguel A1 - Nevanlinna, Heli A1 - Muranen, Taru A. A1 - Lespérance, Bernard A1 - Spurdle, Amanda B. A1 - Neuhausen, Susan L. A1 - Ding, Yuan C. A1 - Wang, Xianshu A1 - Fredericksen, Zachary A1 - Pankratz, Vernon S. A1 - Lindor, Noralane M. A1 - Peterlongo, Paulo A1 - Manoukian, Siranoush A1 - Peissel, Bernard A1 - Zaffaroni, Daniela A1 - Bonanni, Bernardo A1 - Bernard, Loris A1 - Dolcetti, Riccardo A1 - Papi, Laura A1 - Ottini, Laura A1 - Radice, Paolo A1 - Greene, Mark H. A1 - Loud, Jennifer T. A1 - Andrulis, Irene L. A1 - Ozcelik, Hilmi A1 - Mulligan, Anna Marie A1 - Glendon, Gord A1 - Thomassen, Mads A1 - Gerdes, Anne-Marie A1 - Jensen, Uffe B. A1 - Skytte, Anne-Bine A1 - Kruse, Torben A. A1 - Chenevix-Trench, Georgia A1 - Couch, Fergus J. A1 - Simard, Jacques A1 - Easton, Douglas F. T1 - Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers JF - Breast Cancer Research N2 - Introduction: Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2). Methods: To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers and analysed the associations with breast cancer risk within a retrospective likelihood framework. Results: Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 x 10\(^{-4}\)). The association was restricted to mutations proven or predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 x 10\(^{-5}\), P-difference = 0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df P = 0.007; rs1292011 2df P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 x 10\(^{-5}\)) and there was marginal evidence of association with ER- negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049). Conclusions: The present findings, in combination with previously identified modifiers of risk, will ultimately lead to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2 mutation carriers. KW - investigators KW - genetic modifiers KW - mammographic density KW - susceptibility loci KW - ovarian cancer KW - hormone-related protein KW - genome-wide association KW - tumor subtypes KW - alleles KW - consortium Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130449 VL - 14 IS - R33 ER - TY - JOUR A1 - Arnold, Nicole A1 - Braunschweig, Holger A1 - Damme, Alexander T1 - Bis(μ-diisopropyl-phosphanido-\(κ^2\)P:P)bis-[hydrido(triisopropyl-phosphane-κP)platinum(II)] JF - Acta crystallographica. Section E, Structure reports online N2 - In the centrosymmetric molecular structure of the title compound \([Pt_2(C_6H_{14}P)_2H_2)(C_9H_{21}P)_2]\), each \(Pt^{II}\) atom is bound on one side to a phosphane ligand \((PiPr_3)\) and a hydrido ligand. On the other side, it is bound to two phosphanide ligands \((μ-PiPr_2)\), which engage a bridging position between the two \(Pt^{II}\) atoms, forming a distorted square-planar structure motif. The PtPt distance is 3.6755(2)Å. A comparable molecular structure was observed for bis-(μ-di-tert-butyl-phosphanido)bis-[hydrido(triethyl-phosphane)platinum(II)] [Itazaki et al. (2004 ). Organometallics, 23, 1610-1621]. KW - data-to-parameter ratio = 22.3 KW - mean σ(C–C) = 0.004 Å KW - single-crystal X-ray study KW - T = 100 K KW - R factor = 0.018 KW - wR factor = 0.038 Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123723 VL - E68 ER -